Outcomes of <scp>MYC</scp>‐associated lymphomas after R‐<scp>CHOP</scp> with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup <scp>SWOG</scp> S9704

SummaryDouble hit lymphoma (DHL) and double protein‐expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R‐CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow‐up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.

Outcomes of MYC‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704 Journal Articles